Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now Post author:Sam Post published:November 28, 2017 Post category:BioPharma Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace You Might Also Like Exactech Q1 Revenue Up 6% to $69.5 Million On 21% Extremities Growth April 25, 2017 Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain… December 7, 2017 Counsyl Celebrates Anniversary With $80M Funding Round November 6, 2017
Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain… December 7, 2017
